Abe Yoshifusa, Nishiwaki Hiroki, Suzuki Taihei, Noma Hisashi, Watanabe Yoshitaka, Ota Erika, Hasegawa Takeshi
Children's Medical Center, Showa University Koto Toyosu Hospital, Koto-ku, Tokyo, Japan
Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan.
BMJ Open. 2024 Dec 22;14(12):e084088. doi: 10.1136/bmjopen-2024-084088.
Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone. The plasma levels of CoQ10 are reduced in patients with chronic kidney disease (CKD). CoQ10 supplementation can improve mitochondrial function and decrease oxidative stress in these patients. This systematic review will assess the renoprotective effects of CoQ10 supplementation in patients with CKD.
We will include the following studies: (1) randomised-controlled trials, (2) participants with CKD and (3) participants treated with CoQ10 as an intervention. The systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and International Clinical Trials Register databases will be searched for articles without language restrictions in December 2024. The authors will be divided into two groups. Two independent authors will screen the titles and abstracts of all reports extracted via an electronic search. After the initial screening, the authors will independently review the full-text articles and perform a directed content analysis of the extracted data. For outcomes measured using continuous scales of measurement, we will adopt standardised mean differences as the effect measures. We will pool the data using the random-effects model.
No human participants will be involved in the study. On completion of the analysis, the manuscript will be prepared for publication in a peer-reviewed journal.
CRD42021241085.
辅酶Q10（CoQ10）是一种脂溶性维生素样醌类物质。慢性肾脏病（CKD）患者的血浆辅酶Q10水平会降低。补充辅酶Q10可改善这些患者的线粒体功能并降低氧化应激。本系统评价将评估补充辅酶Q10对CKD患者的肾脏保护作用。
我们将纳入以下研究：（1）随机对照试验；（2）CKD患者；（3）接受辅酶Q10作为干预措施的参与者。系统评价方案是根据系统评价和Meta分析方案的首选报告项目制定的。将于2024年12月在MEDLINE、EMBASE、Cochrane对照试验中央注册库和国际临床试验注册数据库中检索无语言限制的文章。作者将分为两组。两名独立作者将筛选通过电子检索提取的所有报告的标题和摘要。初步筛选后，作者将独立审查全文文章，并对提取的数据进行定向内容分析。对于使用连续测量量表测量的结果，我们将采用标准化均数差值作为效应量。我们将使用随机效应模型合并数据。
本研究不涉及人类参与者。分析完成后，将准备稿件在同行评审期刊上发表。
PROSPERO注册号：CRD42021241085。
